Skip to main content

Table 1 Treatment Groups in Patients with Mucosal Leishmaniasis (Peru)

From: Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis

Cohort N Treatment Timing of Treatment
    Study Injections Pentavalent Antimony (Sb5+)
# 1 12
4
5 μg Leish-111f in 25 μg MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SSC1
# 2* 12
4
10 μg Leish-111f in 25 μg MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SSC1
# 3** 12
4
20 μg Leish-111f in 25 μg MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SSC1
  1. 1SSC = Standard single cycle: 28 days of pentavalent antimony (20 mg/kg IV once daily) starting on Day 0.
  2. Sequential enrollment of cohorts: * = after Day 84 of cohort 1; ** = after Day 84 of cohort 2.